Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

Late-Breaking Abstract Submission

Late-breaking abstract procedureThe official late-breaking abstract submission will open from May 2 to 9, 2025 (09:00 CEST). The full late-breaking abstract submission terms & conditions can be found here.

Read more

1st EHA-Balkan Hematology Day

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 1st edition of the EHA-Balkan Hematology Day.

Read more

Meet Irene Roberts, our September volunteer of the month

Can you tell us what you do for EHA and when you started?
I joined EHA in 2003 and shortly afterwards I was lucky enough to be elected as a member of the EHA Board.

Read more

Meet Irene Roberts, our September volunteer of the month

Can you tell us what you do for EHA and when you started?
I joined EHA in 2003 and shortly afterwards I was lucky enough to be elected as a member of the EHA Board.

Read more

EHA-ISHBT Hematology Tutorial

Date: March 1-3, 2024
Format: In-Person
Location: Hyderabad, India

Chairs: P. K.

Read more